Study summary
Targeted therapy plus chemo doubled survival in BRAF V600E colorectal cancer
30.3months median survival, vs 15.1 with standard care
What was tested
Encorafenib (a BRAF-blocking pill) plus cetuximab and FOLFOX chemotherapy against standard chemotherapy, as first treatment for metastatic colorectal cancer with a BRAF V600E mutation (about 1 in 12 cases).
What they found
- Median overall survival was 30.3 vs 15.1 months; progression-free survival was 12.8 vs 7.1 months.
- Serious side effects were 46.1% vs 38.9%.
What it means
Now a first-line standard for BRAF V600E metastatic colorectal cancer.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.